毒蕈碱受体拮抗剂glycopyrorolate在人类和豚鼠气道中的药理特性。

文章的细节

引用

Haddad EB, Patel H, Keeling JE, Yacoub MH, Barnes PJ, Belvisi MG

毒蕈碱受体拮抗剂glycopyrorolate在人类和豚鼠气道中的药理特性。

中华药物学杂志1999 5月;127(2):413-20。

PubMed ID
10385241 (PubMed视图
摘要

1.在本研究中,我们评估了毒蕈碱拮抗剂糖copyrorolate在豚鼠和人气道中的药理特征,并与常用的拮抗剂异丙托溴铵进行了比较。2.甘copyrorolate和异丙托溴铵以浓度依赖的方式抑制efs诱导的豚鼠气管和人气道收缩。甘copyrorolate比异丙托溴铵更有效。3.两种制剂中甘copyrorolate的起始作用(达到50%最大反应的时间)与异丙托溴铵相似。在豚鼠气管中,甘copyrorolate (t1/2[偏移]=26.4+/-0.5 min)的作用偏移(洗脱试验拮抗剂后恢复到50%的反应所需时间)小于异丙托溴铵(81.2+/-3.7 min)。然而,在人气道中,甘copyrorolate的作用时间(t1/2[偏移]>96分钟)明显长于异丙托溴铵(t1/2[偏移]= 59.2+/-17.8分钟)。4. In competition studies, glycopyrrolate and ipratropium bromide bind human peripheral lung and human airway smooth muscle (HASM) muscarinic receptors with affinities in the nanomolar range (K1 values 0.5-3.6 nM). Similar to ipratropium bromide, glycopyrrolate showed no selectivity in its binding to the M1-M3 receptors. Kinetics studies, however, showed that glycopyrrolate dissociates slowly from HASM muscarinic receptors (60% protection against [3H]-NMS binding at 30 nM) compared to ipratropium bromide. 5. These results suggest that glycopyrrolate bind human and guinea-pig airway muscarinic receptors with high affinity. Furthermore, we suggest that the slow dissociation profile of glycopyrrolate might be the underlying mechanism by which this drug accomplishes its long duration of action.

引用本文的药物库数据

药物
药物靶点
药物 目标 种类 生物 药理作用 行动
格隆 毒蕈碱乙酰胆碱受体M2 蛋白质 人类
是的
拮抗剂
细节
格隆 毒蕈碱乙酰胆碱受体M3 蛋白质 人类
是的
拮抗剂
细节